Podcasts about life sciences

Michelle Andrews built a career inside the pharma machine long before anyone knew what “DTC” meant. She helped launch Rituxan and watched Allegra commercials teach America how to ask for pills by name. Then she landed in the cancer fun house herself, stage 4 breast cancer, and learned exactly how hollow all the “journey” slide decks feel when you're the one circling the drain.We talk about what happens when the insider becomes the customer, why pill organizers and wheat field brochures still piss her off, and how she fired doctors who couldn't handle her will to live. You'll hear about the dawn of pharma advertising, the pre-Google advocacy hustle, and what she wants every brand team to finally admit about patient experience.If you've ever wondered who decided windsurfing was the best way to sell allergy meds—or what happens when you stop caring if you make people uncomfortable—listen up.RELATED LINKSMichelle Andrews on LinkedInTrinity Life Sciences – Strategic AdvisoryJade Magazine – Ticking Time Bombs ArticleNIHCM Foundation – Breast Cancer StoryFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

From finding simple recipes to diagnosing complicated illnesses, artificial intelligence (AI) is becoming an increasingly useful part of everyday life, but the space and resources it takes to power that technology is immense and that is hitting close to home for some tribes. The Tonawanda Seneca Nation in New York just filed a lawsuit against a proposed 900,000-square-foot AI data center a mile away from their reservation. Chief Kenith Dale Jonathan says the center would harm air quality, water, and wildlife. We'll hear from the tribe and the potential for data center encroachment elsewhere. We'll also look at how the Trump administration's push to use AI in medicine would benefit or harm Native Americans. GUESTS Christine Abrams (Tonawanda Seneca), office administrator for the Tonawanda Seneca Nation Council of Chiefs Grandell “Bird” Logan (Tonawanda Seneca), media spokesperson for the Tonawanda Seneca Nation Dr. Krystal Tsosie (Diné), assistant professor in the School of Life Sciences at Arizona State University Dr. David Wilson (Diné), associate vice president for health research and professor and chair of Indigenous Health at the University of North Dakota

Send us a textIn this episode of the Life Science Success Podcast, my guest is Ashley Scholz, the Vice President of Marketing at Vector Laboratories, who brings over 16 years of experience in medical devices, diagnostics, and strategic marketing. With a proven track record of driving growth, building high-performing teams, and optimizing commercial strategies, Ashley shares her insights on innovation in the life sciences industry.00:00 Introduction to Life Science Success Podcast00:47 Meet Ashley Scholz: VP of Marketing at Vector Laboratories01:21 Ashley's Career Journey and Experience04:52 Transition to Vector Laboratories06:16 Challenges and Learnings at WL Gore13:10 Building High Performing Teams16:08 Why Vector Labs?21:36 Vector Labs' Mission and Future Focus22:49 Marketing's Role in B2B Transition25:24 Supporting Scientists and Researchers26:35 Innovative Projects and AI Integration29:31 Impact of Recent Acquisitions31:12 Balancing Commercial Growth and Customer-Centricity35:14 Leadership and Organizational Insights38:56 Inspiration and Concerns40:47 Excitement for Future Strategies43:52 Conclusion and Final Thoughts

With external shifts in regulatory uncertainty tied to the IRA, payer pressures, shifting Federal and state policies, and broader scrutiny around pricing, Life Science companies are transforming their operations to deliver better value, grow, and create meaningful impact in the future. In this last episode of the Strategic Transformation series, Mindy McGrath is joined by Karen Baldry and Andrew Sgarlato to discuss what's driving strategic transformations, how life science companies are tackling this and key considerations for leaders embarking on this journey.To learn more about how we can help your team navigate these strategic decisions, reach out to Karen.Baldry@vynamic.com and Andrew.Sgarlato@vynamic.com. Podcast Tags: healthcare, life sciences, healthcare strategy, health innovation, strategic transformation Panel – Mindy McGrath, Karen Baldry, Andrew Sgarlato Research & Production – Mindy McGrath, Karen Baldry, Andrew Sgarlato Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com.

The CISO role is no longer just about protecting IT assets — it's about navigating AI risks, complex regulations, and building digital trust across the enterprise. In an era where digital trust is more important than ever, how do CISOs stay ahead of evolving threats? What impact does AI have on cybersecurity and privacy compliance? And how can organizations empower every employee to contribute to ongoing digital safety? Join cybersecurity expert and former military major Aman Tara in conversation with Punit Bhatia as they explore the evolving responsibilities of CISOs in today's digital landscape. Aman shares why CISOs must think like hackers to stay ahead, how to manage emerging AI threats, and ways to ensure compliance with global data privacy laws. If you want to understand the future of cybersecurity leadership and how to foster trust in an AI-driven era, this episode is a must-watch! KEY CONVERSION 00:01:44 What is Digital Trust for Aman Tara 00:02:44 What role does the CISO play in creating Digital Trust? 00:04:59 How to manage overlap in a CISO role with privacy function 00:06:17 Do you have regular meetings with privacy counterparts? 00:08:19 Impact of AI and emerging technologies on the role of CISO 00:09:58 How Should a CISO respond when using unsafe tools and create risk in organization? 00:12:00 What can everyone do to ensure ongoing digital trust and safety? 00:15:17 Amman's Book and Personal Journey  ABOUT GUEST Aman Tara is an ex-military Major and a qualified attorney. He holds an associate diploma in Software Engineering, a bachelor's degree in Life Sciences and Economics, a degree in Law, and his MBA from Iowa, USA. He is a Certified Information System Auditor, Certified Data Privacy Solutions Engineer, Certified Fraud Examiner, Certified Amazon Web Services Cloud Practitioner and a Scrum Master. He has also done a Cybersecurity course at Massachusetts Institute of Technology (MIT).  After serving in the military for a decade in various combat and staff roles, he moved to the corporate world in 2011. He has worked on IT audits, IT security and Cybersecurity assessments, Third Party Risk Management projects for various Fortune 500 companies across the USA and South Asia. Presently, he is the Executive Director for one of the world's largest banks, working in their Cybersecurity department and Board of Directors of three Non-Profit Organizations based outside of the USA.  He has been featured in articles overseas and invited as speaker for various US based and international seminars. He conducts workshops for corporates on stress management, hosts a live radio show every week in Texas, USA, and has also authored a book ‘Just Did It'.  ABOUT HOST Punit Bhatia is one of the leading privacy experts who works independently and has worked with professionals in over 30 countries. Punit works with business and privacy leaders to create an organization culture with high privacy awareness and compliance as a business priority. Selectively, Punit is open to mentor and coach professionals.  Punit is the author of books “Be Ready for GDPR' which was rated as the best GDPR Book, “AI & Privacy – How to Find Balance”, “Intro To GDPR”, and “Be an Effective DPO”. Punit is a global speaker who has spoken at over 30 global events. Punit is the creator and host of the FIT4PRIVACY Podcast. This podcast has been featured amongst top GDPR and privacy podcasts.  As a person, Punit is an avid thinker and believes in thinking, believing, and acting in line with one's value to have joy in life. He has developed the philosophy named ‘ABC for joy of life' which passionately shares. Punit is based out of Belgium, the heart of Europe.  RESOURCES Websites www.fit4privacy.com,www.punitbhatia.com, https://www.linkedin.com/in/aman-tara-cisa-cdpse-cfe-b6095483/ Podcast https://www.fit4privacy.com/podcast Blog https://www.fit4privacy.com/blog YouTube http://youtube.com/fit4privacy   

Tata Consultancy Services (TCS), a global leader in IT services, consulting, and business solutions, has collaborated with MIT Sloan Management Review (MIT SMR) to launch a new research series to explore the next phase of human and AI collaboration in large enterprises. As enterprises the world over are proactively investing in deploying AI-led solutions to transform their business operations, this multi-sectoral study deeply examines the new paradigms that will redefine the use of AI in global enterprise environments. In a series of research articles covering Manufacturing, Retail and Consumer Packaged Goods, BFSI, Life Sciences and Healthcare, Energy, Resources and Utilities, and Communications, Media and Technology sectors, the study investigates how business leaders are deploying AI augmented solutions to gain a competitive edge from better decisions. The study on the theme of Human-Centric AI spans six key sectors and finds that generative and predictive AI can initiate a transformative change that drives competitive advantage. The year-long research that was conceptualised and executed jointly by MIT SMR and TCS drew insights experts and pioneers from organisations such as Walmart, Meta, MasterCard, and Pernod Ricard. The research identifies one critical shift: AI is moving from advisor to architect. In simple terms, AI's value shifts from improving business processes to improving the quality of options to facilitate better decision-making. Companies that master this transition are pulling ahead of those still trapped in traditional decision-making frameworks. TCS' industry expertise in strategising and supporting large global organisations in their AI-led digital transformation journeys using both generative and predictive AI along with the academic rigor of MIT SMR bring forth new and fresh thinking about using AI to augment and inform Human Intelligence. The collaborative research has revealed the emergence of intelligent choice architectures (ICAs) - a new paradigm where human-centric AI systems proactively participate in structuring and shaping strategic decisions by generating novel options, predicting outcomes, and guiding choices. Michael Schrage, Research fellow at MIT Sloan's Initiative on the Digital Economy and report coauthor, said, "ICAs flip the script. They do not just learn from decisions - they learn how to improve the environment in which decisions are made. That's not analytics, that's architecture." Ashok Krish, Head, AI Practice, TCS, said, "By augmenting human judgment with machine intelligence, ICAs shift AI from task automation to building superior decision environments for complex multi-factorial situations, enabling more trackable, traceable outcomes that ensure accountability. They help align talent development strategies with organisational goals, making it easier to identify and nurture high-potential employees in the AI-era. Ultimately, ICAs foster environments where human judgement and AI work together seamlessly to create connected organisation intelligence, where smarter and more informed decisions are made." Through this new study with MIT SMR, TCS extends its long-standing commitment to understand and uncover new trends in the industry and aid partners in integrating new technologies and frameworks. Over the years, TCS has collaborated with MIT SMR on industry research about direct-to-consumer enterprises, workforce empowerment, digital inclusion, retailing, and customer experience among others. Through its partnership with MIT SMR and 50 other academic institutions, TCS curates collective intelligence that enterprises can tap into. The sector-specific study provides compelling examples of ICAs in action to optimize choices, reallocate decision rights, and boost their bottom lines. Organisations using GenAI have helped achieve higher productivity and efficiency and cut costs while unlocking newer growth opportunities. In retail, AI enables retailers to both anticipate and address ma...

In this episode of Tiny Show and Tell Us, we cover squirrel pox — a disease that hasn't had a huge impact in the United States but has decimated populations of squirrels in the UK. Then we talk about the story that Napoleon's army lost the Battle of Waterloo because the military uniforms used tin buttons that broke apart in cold temperatures, making it harder for the troops to survive. But is there any truth to that story? We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if the C-suite wasn't the destination—but a stop on the way to something more fulfilling?In this heartfelt episode of Women Leaders on the Move, host Natalie Benamou sits down with Jennifer Peters, a visionary Life Sciences Executive and an author to the upcoming anthology Power of Next: Bold Moves by Design. Jennifer shares her deeply personal journey, one shaped by resilience, reinvention, and the power of saying “yes” to unexpected turns.From starting over in a new city as a single mom to launching a successful business during the 2008 recession, Jennifer reveals how nonlinear paths often lead to the most meaningful destinations. She opens up about navigating ageism, redefining success, and why letting go of titles can be the ultimate power move.✨ In this episode, you'll hear:How to reframe "overqualified" into a leadership strengthWhy embracing change—at any age—can be your greatest advantageA moving story of courage, legacy, and finding silver linings in unexpected moments"I realized I've accomplished more than I thought I did—and I'm proud of the decisions I've made, even the ones that didn't go as planned. There's always a silver lining." – Jennifer PetersWhether you're navigating a career pivot or redefining what's next, Jennifer's story will leave you feeling empowered to make bold moves—by your own design.

Up to 3,500 FDA staffers received their final walking papers Monday after the U.S. Supreme Court found last week that the government is “likely to succeed” in arguing that its overhaul of HHS is “lawful.” Meanwhile, FDA Commissioner Marty Makary floated policy changes for the agency, including a proposal to lower prescription drug user fees for the next iteration of the program, and one to offer speedier reviews to companies willing to lower the cost of their drugs.  Last week, the regulator opened its cache of complete response letters (CRLs), offering transparency into the rationale behind more than 200 recent rejections for ultimately approved therapies, including those for Eli Lilly's Alzheimer's drug Kisunla and Sarepta's Duchenne muscular dystrophy (DMD) treatment Vyondys 53. The FDA did not, however, release the CRLs for two new rejections: those of therapies from Ultragenyx and Capricor Therapeutics in Sanfilippo syndrome type A and cardiomyopathy associated with DMD, respectively. It was an especially rough week for Ultragenyx, which also, along with partner Mereo BioPharma, released seemingly negative Phase II/III data for their osteogenesis imperfecta therapy.  On a more positive note, two bustling therapeutic spaces continue to see positive data. In obesity, Hengrui Pharma's Kailera Therapeutics–partnered dual GLP-1/GIP receptor agonist elicited 17.7% average weight loss in a pivotal Chinese trial. And the psychedelic therapeutics space is again generating excitement with two recent positive readouts in treatment-resistant depression. BioSpace took a deep dive into the market reaction to these readouts for Compass Pathways and Beckley Psytech and atai Life Sciences, and what exactly investors are looking for in a successful psychedelic therapy.  Finally, we examine the progress of AI biotech unicorns and kick off our series on women in biopharma with profiles on Mayo Venture Partner Audrey Greenberg and the all-female CEO/R&D tandem at Acadia Pharmaceuticals.  

Dr. Anne Marie Morse walks into the studio like a one-woman Jersey Broadway show and leaves behind the best damn TED Talk you've never heard. She's a neurologist, sleep medicine doc, narcolepsy expert, founder of D.A.M.M. Good Sleep, and full-time myth buster in a white coat. We talk about why sleep isn't a luxury, why your mattress does matter, and how melatonin is the new Flintstones vitamin with a marketing budget. We unpack the BS around sleep hygiene, blow up the medical gaslighting around “disorders,” and dig into how a former aspiring butterfly became one of the loudest voices for patient-centered science. Also: naps, kids, burnout, CPAPs, co-sleeping, airport pods, the DeLorean, and Carl Sagan. If you think you're getting by on five hours of sleep and vibes, you're not. This episode will make you want to take a nap—and then call your doctor.RELATED LINKSdammgoodsleep.com: https://www.dammgoodsleep.comLinkedIn: https://www.linkedin.com/in/anne-marie-morse-753b2821/Instagram: https://www.instagram.com/dammgoodsleepDocWire News Author Page: https://www.docwirenews.com/author/anne-marie-morseSleep Review Interview: https://sleepreviewmag.com/practice-management/marketing/word-of-mouth/sleep-advocacy-anne-marie-morse/Geisinger Bio: https://providers.geisinger.org/provider/anne-marie-morse/756868SWHR Profile: https://swhr.org/team/anne-marie-morse-do-faasm/FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

This week, Lynnsey and Lauren are joined by Maynard Nexsen attorney Jennifer McEwen, who helps clients with business planning, estate and trust planning, and tax planning. Jennifer shares essential business strategies for physicians and life sciences entrepreneurs, from succession planning and shareholder agreements to navigating ownership restrictions and tax-smart business structures. Whether you're launching a healthcare or life sciences startup or preparing for retirement as a provider, Jennifer and Lauren offer actionable insights to help protect your business and your legacy. Tune in now!

On this week's episode of Top in Tech, Megan Stagman, Director, UK TMT, is joined by Charlie Norell, Senior Associate in GC's Health & Life Sciences practice, to unpack the UK's recently published 10-Year Health Plan and what it means for the future of healthcare innovation. They explore how the Plan aims to reshape the NHS, with a focus on the government's desired shift from analogue to digital and harnessing the latest technologies. They reflect on next steps for the proposed Single Patient Record, the expanded role of the NHS App, new "Global Institutes" and regional innovation zones, and dig into the political drivers and fiscal considerations behind the Plan. The discussion covers the opportunities this creates for MedTech, life sciences, and digital health, alongside key challenges such as funding gaps and structural reform. Hosted on Acast. See acast.com/privacy for more information.

Leslie Galer is the Owner of Collaborative Quality Improvement LLC, A Quality and Food Safety Consulting company. She also subcontracts for Commercial Quality Assurance and Food Safety Solutions. Leslie is a highly efficient and results-driven professional with Black Belt and Certified Quality Engineer (CQE) certifications. Over 20 years experience in the Food and Dietary Supplements Industries, focusing on: R&D, factory food safety and quality systems, and quality management. Before founding Collaborative Quality Improvement LLC, Leslie worked in Leadership and Management roles at Kraft Heinz and Walgreens. The Industry 4.0 Podcast with Grantek delivers a look into the world of manufacturing, with a focus on stories and trends that lead to better solutions.   Our guests will share tips and outcomes that will help improve your productivity. You will hear from leading providers of Industrial Control System hardware and software, Grantek experts and leaders at best-in-class industry associations that serve Life Sciences and Food & Beverage manufactures.

In this episode, we explore how TileDB, an innovative data system originally developed at MIT and Intel Labs, is revolutionizing healthcare and life sciences data management. We'll dive deep into how TileDB's universal data engine efficiently handles complex scientific data - from genomic sequences to medical imaging - in a unified format, and learn how healthcare organizations can leverage TileDB on AWS to accelerate research, improve collaboration, and reduce infrastructure costs. Join host AWS Solutions Architect for HCLS Gokhul Srinivasan and guest Devika Garg form TileDB as they discuss real-world applications in precision medicine, genomic analysis, and how TileDB is transforming the way healthcare providers manage and analyze patient data.To Learn More:https://www.tiledb.com/AWS Hosts: Nolan Chen & Gokhul SrinivasanEmail Your Feedback: rethinkpodcast@amazon.com

For healthcare providers, insurance is a necessary business strategy. For patients, it's stress inducing and often, unsupportive. In this episode, host Mike Huffaker sits down with Ben Baenen, Director of Healthcare and Life Sciences at West Monroe, to explore the evolving landscape of dental technology, real-time claims processing, and the impact of AI on the industry. Discover how collaboration between payers and providers is reshaping the dental ecosystem, why data standardization matters more than ever, and what emerging trends like membership plans mean for the future of dental benefits. Trust erosion and friction are all too familiar in the world of dental insurance claims. But the right technology adoption, practice operations and industry innovation can take us ahead of the curve.

Emerson's Jordan Johnson & Rachel Wright join Jim Cahill in this podcast to discuss challenges in the Life Sciences sector and the role of Emerson Life Savers serve in collaborating closely with them to address and overcome these challenges.

In January, 1997, David Nierenberg was a physician at Dartmouth‐Hitchcock Medical Center, specializing in toxicology. Chemist Karen Wetterhahn was placed in his care. When she arrived at the hospital, Karen was slurring her speech and having difficulty balancing and with coordination. What David soon learned was that her symptoms were all due to a few tiny drops of a compound called dimethylmercury. Today's episode focuses on two lab accidents that had a profound impact on research communities, and that inspired changes that have likely saved the lives of scientists and other workers since. The first story is that of Karen Wetterhahn who, in the 1990s was a professor of chemistry at Dartmouth College whose lab focused on heavy metal toxicity. The other story is about fatal prion protein exposures in France that led to a temporary moratorium in 2021. Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

July 9, 2025: Todd Barton, AVP, Enterprise Sales Engineering at Rubrik, and PV SubbaRao, SVP of Global Healthcare and Life Sciences from Rackspace, reveal how they're revolutionizing healthcare's approach to cyber resilience through their groundbreaking partnership. The conversation delves deep into the concept of Isolated Recovery Environments (IRE) and the "Minimum Viable Hospital" - but what exactly does it mean to operate at bare minimum while maintaining patient care, and how do you determine what systems are truly essential when every second counts? As healthcare organizations grapple with doing more with less, these experts explore how proper cyber recovery planning can actually unlock 20-25% cost savings that can be reinvested into the innovations hospitals need.  Key Points: 05:04 Preemptive Recovery  10:21 Minimum Viable Hospital and IRE 20:21 Cost and Productivity Optimization X: This Week Health LinkedIn: This Week Health Donate: Alex's Lemonade Stand: Foundation for Childhood Cancer

Morrison Foerster partners Kate Driscoll and Nate Mendell, both former federal prosecutors and members of the firm's Investigations + White Collar Defense Group, hosted the tenth episode of When Your Life Sciences Are on the Line, where leading practitioners and thought leaders share the insights and advice needed to manage business and legal risk in the life sciences sector. In this episode, Kate and Nate have a compelling discussion with Daralyn Durie, a partner in Morrison Foerster's Life Sciences and IP Litigation Groups recognized as one of the country's leading trial lawyers. Their conversation delves into the complexities of trial practice within the life sciences sector, highlighting the strategic considerations that drive companies to pursue litigation despite the inherent risks and costs.

In this episode, I go over 8 lessons to maximize your first 90 days in Life Sciences. These include understanding the impact of their roles, adopting a professional mindset, passing the first 90-day test, avoiding the 'silent trap,' finding mentors, valuing feedback, mastering systems, and taking responsibility for their careers. Subhi emphasizes that these lessons can significantly accelerate growth and career advancement for newcomers to the industry.Link to course: subhisaadeh.gumroad.com/l/6figurebiomedical00:00 Introduction: Starting Your Career Journey00:54 Lesson 1: Your Role Can Have a Big Impact02:55 Lesson 2: Adopting a Professional Mindset04:06 Lesson 3: The First 90 Days Are Crucial05:09 Lesson 4: Avoiding the Silent Trap06:35 Lesson 5: Finding the Right Mentors07:14 Lesson 6: Embrace Feedback as Fuel07:51 Lesson 7: Mastering the Systems08:47 Lesson 8: Taking Responsibility for Your Career09:19 Conclusion and Additional ResourcesSubhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations and R&D he's worked in Large Medical Device/Pharma organizations to support the development and launch of Hardware Devices, Disposable Devices, and Combination Products for Vaccines, Generics, and Biologics. Subhi serves currently as the International Committee Chair for the Combination Products Coalition(CPC) and as a member of ASTM Committee E55 and also served as a committee member on AAMI's Combination Products Committee.For questions, inquiries or suggestions please reach out at letscombinate.com or on the show's LinkedIn Page.

Gigi Robinson grew up with Ehlers-Danlos syndrome, a disease that turns your joints into overcooked spaghetti. Instead of letting it sideline her, she built a career out of telling the truth about invisible illness. We talk about what it takes to grow up faster than you should, why chronic illness is the worst unpaid internship, and how she turned her story into a business. You'll hear about her days schlepping to physical therapy before sunrise, documenting the sterile absurdity of waiting rooms, and finding purpose in the mess. Gigi's not interested in pity or polished narratives. She wants you to see what resilience really looks like, even when it's ugly. If you think you know what an influencer does, think again. This conversation will challenge your assumptions about work, health, and what it means to be seen.RELATED LINKSGigi Robinson Website: https://www.gigirobinson.comLinkedIn: https://www.linkedin.com/in/gigirobinsonInstagram: https://www.instagram.com/itsgigirobinsonTikTok: @itsgigirobinsonA Kids Book About Chronic Illness: https://akidsco.com/products/a-kids-book-about-chronic-illnessFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Daniel Castner, AIA, LEED AP is Principal and Director of the Life Science practice at Mancini Duffy where he is passionate about workplace strategy with a focus on research labs, medical space, and anything requiring a helpful orchestrator of AEC coordination. Mike Petrusky asks Dan about his experiences helping the IFMA community, the importance of client relationships and the use of technology in workplace strategy. They explore design trends and emphasize the core elements of flexibility and being intentional when delivering spaces that meet the needs of the workforce. Dan believes that change management has evolved to focus more on the employee experience and wellbeing, rather than just specific projects, so using sensors and analytics can help leaders understand human priorities. Dan's unique experience in life science workplaces have led him to focus on building a culture of collaboration and innovation, so he shares some encouragement, practical advice and the inspiration you will need to be a Workplace Innovator! Take the Eptura™ Podcast Survey: https://forms.office.com/r/jY577CbNcx Connect with Dan on LinkedIn: https://www.linkedin.com/in/danielcastner/ Learn more about Mancini Duffy: https://www.manciniduffy.com/ Discover free resources and explore past interviews at: https://www.workplaceinnovator.com/ Learn more about Eptura™: https://eptura.com/ Connect with Mike on LinkedIn: https://www.linkedin.com/in/mikepetrusky/  

In this insightful interview with Blue Box Asset Mangement's Porfolio Manager Mark Dainty we talk about precision medicine and life sciences, his investment strategy, and how he constructs a portfolio of "developers" vs "enablers". We also talk about 3 stocks in the fund. We hope you enjoy listening!  *~*~*~*~*  Get access to all of Speedwell Research's in-depth Research Reports here. If you need help getting Speedwell added as an approved research vendor for your investment firm, please reach out to info@speedwellresearch.com  -*-*-*-*-*-*-*-*-*-*- Show Notes (0:00) — What is Precision Medicine and Life Sciences (11:15) — Small Markets, but Higher Prices (22:24) — Why Precision Medicine is like Dating Apps (27:56) — Investment Strategy and Portfolio Construction (47:20) — Two Stocks: Natera ($NTRA) and Guardant Health ($GH) (54:24) — Risk of the Unknown? (1:02:55) — Revolutions Medicines ($RVMD) (1:11:10) — Financial Modeling -*-*-*-*-*-*-*-*-*-*- Become a Speedwell Member here to gain access to *all* of our in-depth research reports and more!   Sign up for Speedwell's free newsletter and weekly memos here *~*~*~*~*  Follow Us: Twitter: @Speedwell_LLC Threads: @speedwell_research Email us at info@speedwellresearch.com for any questions, comments, or feedback. -*-*-*-*-*-*-*-*-*-*- Disclaimer Nothing in this podcast is investment advice nor should be construed as such. Contributors to the podcast may own securities discussed. Furthermore, accounts contributors advise on may also have positions in companies discussed. Please see our full disclaimers here:  https://speedwellresearch.com/disclaimer/

Nick Capman talks with Marcia Baroni—a microbiologist with 27 years in global pharma-quality leadership—about reframing quality from a controllable expense to a strategic asset. Baroni contrasts “bad-quality” costs (scrap, recalls, deviations) with “good-quality” investments (testing, preventive controls, oversight) and explains why the latter pay for themselves in resilience and brand value. She illustrates the stakes with a $600 million nationwide OTC-drug recall caused by chemically treated pallets—an error frontline staff flagged but a weak quality culture ignored. The conversation dives into building psychological safety and metrics that drive the right behaviors, not under-reporting, shifting quality from “policing” to cross-functional partnership, and practical first steps executives can take to gauge their current maturity and start investing for future yield._____The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus in Quality Assurance, Regulatory Affairs, and Clinical Operations. For project or resource needs, visit ⁠⁠https://www.thefdagroup.com/

Review of Jamie L. Jensen, Steven L. Peck, Ugo A. Perego, and T. Benjamin Spackman, eds. The Restored Gospel of Jesus Christ and Evolution. Provo, UT: College of Life Sciences, Brigham Young University, 2025. 272 pgs. Abstract: This review critically evaluates The Restored Gospel of Jesus Christ and Evolution, a multi-author volume that seeks to harmonize […] The post Reconciling Evolution by Faith or Framing? first appeared on The Interpreter Foundation.

Dive into Episode #148 of the Psych Health and Safety USA Podcast, featuring host Dr. I. David Daniels, PhD, CSD, VPS, and special guest Gloria Hartley, the Civil Rights Compliance Coordinator at the College of Agriculture and Life Sciences at Virginia Tech University. She is also the child of immigrants, a veteran of the United States Navy, and has spent over a decade in and around the human resource space in both the private and public sectors. One of her professional goals has been to convert conversations about Civil and Human Rights into practical language and steps that people can take to protect workers and the organization. Civil rights and psychosocial safety are deeply interconnected. Civil rights ensure that individuals are protected from discrimination and have equal access to opportunities, which is fundamental for creating a safe and inclusive environment. Psychosocial safety, however, refers to the psychological and social conditions that allow individuals to feel safe, respected, and valued in their communities and workplaces. Individuals are more likely to experience psychosocial safety when civil rights are upheld because they are protected from discrimination, harassment, and other forms of harm. This creates an environment where people can express themselves freely, participate fully in society, and feel a sense of belonging. Conversely, when civil rights are violated, it can lead to a lack of psychosocial safety, resulting in stress, anxiety, and other adverse mental health outcomes. LinkedIn Profile https://www.linkedin.com/in/gloriamhartley/

Join us on Pathmonk Presents with Lauren Alexander, CMO of Qualia Life Sciences, a leader in brain health supplements since 2015. Lauren shares how Qualia uses complex systems science to create high-quality nootropics for biohackers, executives, and athletes. Discover strategies for leveraging meta advertising, building an educational website hub, and optimizing subscription models for e-commerce success. Learn tips for prioritizing customer education and managing mental energy to boost productivity. Tune in for actionable insights to drive growth and inspire healthier, sharper minds! Use code PATHMONK for 15% off at qualialife.com.   

In this episode of Tiny Show and Tell Us, we talk about how climate change may impact the effectiveness of mental health medications and how heat waves impact mental health more generally. Then we cover how fetal heart rates can change depending on which language they're hearing while in the womb. We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This is the daily Tech and Business Report. Today, KCBS Radio anchor Holly Quan spoke with Bloomberg's Ilena Peng. Pistachio farmers in California are having a great year, thanks in part to a chocolate shop in the United Arab Emirates.

The U.S. Supreme Court closed out its session before breaking for summer on Friday, ruling that decisions around coverage of HIV PrEP drugs should be left up to the U.S. Preventive Services Task Force. The ruling thwarted a lawsuit brought by a group of insurance providers who challenged the Affordable Care Act's requirement that they cover preventive medicines, such as HIV drugs, recommended by the task force. The high court also determined that members of this task force can be removed at will by HHS Secretary Robert F. Kennedy Jr.Speaking of HHS committees from which members have been removed at will by Kennedy, the CDC's revamped Advisory Committee on Immunization Practices convened last week for its first meeting since the roster overhaul, where a vote on Merck's recently approved RSV-targeting monoclonal antibody Enflonsia and a discussion around the inclusion of preservative thimerosal in influenza vaccines was on the docket, but an expected vote on Moderna's mRNA-based RSV shot mRESVIA was not.Also dominating the headlines on Friday was the FDA's decision to remove the Risk Evaluation and Mitigation Strategies (REMS) program from the six approved CAR T therapies it was applied to. Analysts and patient groups lauded the move, which is expected to potentially double access to these life-saving therapies, saying it reflects “thoughtful consideration of real-world evidence” and “regulatory trust.”Willliam Blair noted that it could be a “positive signal” to companies developing CAR T therapies for autoimmune diseases, which now includes AbbVie. In an all-cash buyout on Monday, the Illinois-based pharma dropped $1.2 billion for Capstan Therapeutics and its in vivo edited CAR T therapy for B cell–mediated autoimmune diseases. M&A has been on an uptick of late, and private equity companies—such as those that snapped up bluebird bio—are also getting in on the game.Finally, after Lykos Therapeutics' high profile failure last summer, the psychedelics space is heating up once again. While a Phase III readout of Compass Pathways' psilocybin drug last week in treatment-resistant depression received a muted reaction from investors, the response to a Phase II readout for Beckley Psytech and atai Life Sciences' intranasal psychedelic was more positive.

Episode Description:If you've ever wondered what happens when a Bronx-born pediatric nurse with stage 4 colon cancer survives, raises a kid, becomes a policy shark, and fights like hell for the ignored, meet Vanessa Ghigliotty. She's not inspirational. She's a bulldozer. We go way back—like pre-Stupid Cancer back—when there was no “young adult cancer movement,” just a handful of pissed-off survivors building something out of nothing. This episode is personal. Vanessa and I built the plane while flying it. She fought to be heard, showed up in chemo dragging her kid to IEP meetings, and never stopped screaming for the rest of us to get what we needed. We talk war stories, progress, side-eyeing advocacy fads, TikTok activism, gatekeeping, policy wins, and why being loud is still necessary. And yeah—she's a damn good mom. Probably a better one than you. You'll laugh. You'll cry. You'll want to scream into a pillow. Come for the nostalgia. Stay for the righteous anger and iced coffee.RELATED LINKSVanessa on LinkedInColorectal Cancer Alliance: Vanessa's StoryZenOnco Interview with VanessaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if a mouse could help shape the future of cancer treatment? In this episode of Sounds of Science, host Mary Parker speaks with Julia Schüler, DVM, PhD, Research Director and Therapeutic Area Lead for Oncology at Charles River. Julia shares how patient-derived xenograft (PDX) models—often described as “avatars” of human tumors—are transforming preclinical oncology research. From preserving tumor heterogeneity to improving translational relevance, PDX models are accelerating the discovery of more effective, personalized therapies. Tune in as we explore how these advanced models are driving innovation across the drug development pipeline—from target discovery to clinical trial design.Show NotesPDX Tumor Organoids : A New Tool in Drug Discovery Testing Realm Organoids: Some Assembly Required Patient-Derived Xenografts- PDX Models 3D Tumor Models In Vitro PDX Assays 

This is the daily Tech and Business Report. Today, KCBS Radio anchor Holly Quan spoke with Bloomberg's Brian K. Sullivan. Big cuts are coming to the National Oceanic and Atmospheric Administration, as the new budget proposal slashes the agency's budget by $1.5 billion. That will result in an estimated 2,200 jobs being cut, which is about 18% of the Administration's workforce.

What if the next virus isn't natural, but deliberately engineered and used as a weapon? As geopolitical tensions rise and biological threats become more complex, health security and life sciences are emerging as critical pillars of national defense.In the special edition episode from our new series, “The Ripple Effect: Investing in Life Sciences”, host Dan Riskin is joined by two leading voices at the intersection of biotechnology and defense: Dawn Meyerriecks, former CIA Deputy Director for Science and Technology and current member of the National Security Commission on Emerging Biotechnology, and Jason Kelly, co-founder and CEO of Ginkgo Bioworks. Together, they explore the dual-use nature of biotechnology and the urgent need for international oversight, genetic attribution standards, and robust viral surveillance. From pandemic preparedness and fragile supply chains to AI-driven lab automation and airport biosurveillance, their conversation highlights how life science innovation strengthens national resilience and strategic defense.This timely conversation follows the June 25th, 2025 Hague Summit Declaration, where NATO allies pledged to invest 5% of GDP in defense by 2035—including up to 1.5% on resilience and innovation to safeguard critical infrastructure, civil preparedness, networks, and the defense industrial base. This limited series, produced by GZERO's Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment. Subscribe to “The Ripple Effect: Investing in Life Sciences” series on your preferred podcast platform.Look for the next episode of the GZERO World with Ian Bremmer podcast when we kick off our eighth season on July 5, 2025.Host: Dan RiskinGuests: Jason Kelly, Dawn Meyerriecks Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published.

John Bates, Curator and Section Head, Life Sciences, The Field Museum, joins John Williams to talk about the changes made to McCormick Place in Chicago that has kept migrating birds from hitting windows and reducing deaths by 95 percent.

John Bates, Curator and Section Head, Life Sciences, The Field Museum, joins John Williams to talk about the changes made to McCormick Place in Chicago that has kept migrating birds from hitting windows and reducing deaths by 95 percent.

What if the next virus isn't natural, but deliberately engineered and used as a weapon? As geopolitical tensions rise and biological threats become more complex, health security and life sciences are emerging as critical pillars of national defense.In the special edition episode from our new series, “The Ripple Effect: Investing in Life Sciences”, host Dan Riskin is joined by two leading voices at the intersection of biotechnology and defense: Dawn Meyerriecks, former CIA Deputy Director for Science and Technology and current member of the National Security Commission on Emerging Biotechnology, and Jason Kelly, co-founder and CEO of Ginkgo Bioworks. Together, they explore the dual-use nature of biotechnology and the urgent need for international oversight, genetic attribution standards, and robust viral surveillance. From pandemic preparedness and fragile supply chains to AI-driven lab automation and airport biosurveillance, their conversation highlights how life science innovation strengthens national resilience and strategic defense.This timely conversation follows the June 25th, 2025 Hague Summit Declaration, where NATO allies pledged to invest 5% of GDP in defense by 2035—including up to 1.5% on resilience and innovation to safeguard critical infrastructure, civil preparedness, networks, and the defense industrial base. This limited series, produced by GZERO's Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment. Subscribe to “The Ripple Effect: Investing in Life Sciences” series on your preferred podcast platform.Look for the next episode of the GZERO World with Ian Bremmer podcast when we kick off our eighth season on July 5, 2025.Host: Dan RiskinGuests: Jason Kelly, Dawn Meyerriecks Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published.

John Bates, Curator and Section Head, Life Sciences, The Field Museum, joins John Williams to talk about the changes made to McCormick Place in Chicago that has kept migrating birds from hitting windows and reducing deaths by 95 percent.

Shannon Gregg is the President of Cloud Adoption Solutions, who helps Life Sciences and Technology companies maximize their Salesforce potential through PhD-backed research in user adoption and change management.Through her expertise in combining people, process, and technology, Shannon guides organizations in regulated industries to unlock sustainable growth while maintaining compliance and driving revenue.Now, Shannon's remarkable journey of completing her PhD, battling stage 3b cancer, and growing her company to a 14-person team demonstrates how determination can fuel success.And while balancing roles as president, professor, and mom, she's even found time to compete on a Mom Jazz dance team and judge international dance competitions, proving that excellence doesn't mean sacrificing joy.Here's where to find more:https://cloudadoption.solutionshttps://shannongregg.comhttps://www.linkedin.com/in/shannonjgregghttps://www.youtube.com/@newtechdemoshttps://www.youtube.com/@shannonj.greggphdmba3314https://thedanceworlds.net/meet-the-judges___________________________________________________________Welcome to The Unforget Yourself Show where we use the power of woo and the proof of science to help you identify your blind spots, and get over your own bullshit so that you can do the fucking thing you ACTUALLY want to do!We're Mark and Katie, the founders of Unforget Yourself and the creators of the Unforget Yourself System and on this podcast, we're here to share REAL conversations about what goes on inside the heart and minds of those brave and crazy enough to start their own business. From the accidental entrepreneur to the laser-focused CEO, we find out how they got to where they are today, not by hearing the go-to story of their success, but talking about how we all have our own BS to deal with and it's through facing ourselves that we find a way to do the fucking thing.Along the way, we hope to show you that YOU are the most important asset in your business (and your life - duh!). Being a business owner is tough! With vulnerability and humor, we get to the real story behind their success and show you that you're not alone._____________________Find all our links to all the things like the socials, how to work with us and how to apply to be on the podcast here: https://linktr.ee/unforgetyourself

Join us for an enlightening conversation with Dr. Bo Wen, a leading AGI specialist, cloud architect, and staff research scientist at IBM. With expertise in generative AI, human-AI interaction, and computational analysis, Dr. Wen discusses the rapid advancements in AI and their potential impact on the future of human communication and collaboration. Dr. Wen has been instrumental in IBM's Healthcare and Life Sciences division, pioneering AI-driven health solutions, wearables, and IoT technologies. His diverse background spans digital health, cognitive science, computational psychiatry, and physics, giving him a unique perspective on AI's capabilities and risks. In this episode, we explore: Wen's early predictions on AI breakthroughs

Smart manufacturing is “nearly universal” with 95% of manufacturers saying they are using or evaluating smart technology, according to a new survey from Rockwell Automation. Greg Slabodkin Read by Brittany Duncan

Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jeanne Taylor Hecht, Chief Executive Officer and Chairwoman at Lexitas. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeanne, covering: How Jeanne's various roles have equipped her to become a more rounded CEO and board member. How a stint in Asia led Jeanne to develop her strategy playbook, including the importance of the client's voice. Jeanne's journey, taking on eight different boards and becoming a serial investor and advisor... and how that did not happen by accident. She said that having a strong relationship with a PE firm and missing the hands-on, day-to-day role of being a CEO led her back to the hot seat. Understanding why has being a specialist ophthalmology CRO given Lexitas traction with small to medium biotechs, and what is the future in store for CROS? Jeanne's industry career spanned over twenty-five years as a Board member and Chief Executive Officer of multiple companies, including CEO at Ora and Senior Executive at Median Technologies, IQVIA, Decision Biomarkers, and the UNC Oncology Protocol Office. Jeanne also launched and expanded a Life Sciences consulting practice that supported companies with sales, marketing, and market growth strategies and advisory and board work. She is primarily motivated by helping to bring relief to patients.  Jeanne is an active Advisory Board Member for the University of North Carolina Chapel Hill Kenan-Flagler's Business School and Lecturer at the business school. She contributed to the creation of Wake Forest University's master's in clinical research program and remains an active industry advisor to the school. She holds a Bachelor of Science from the University of Michigan and a Master of Business Administration from the university's Ross School of Business. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!  Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

This is a free preview of a paid episode. To hear more, visit www.louiseperry.co.ukMy guest today is Marco Del Giudice, Associate Professor in the Department of Life Sciences at the University of Trieste. We spoke about one of Marco's key research interests: evolutionary psychopathology. That is, how our evolutionary history influences mental illness. We spoke about how gender differences in personality influence psychopathology, part…

Today's guest is Annabel Romero, Specialist Leader focusing on AI for Drug Discovery at Deloitte and a structural biologist by training. Deloitte is a global consulting firm known for its work in digital transformation, data strategy, and AI adoption across regulated industries. Annabel joins Emerj Editorial Director Matthew DeMello to explore how AI systems are being designed to think more like scientists—particularly in protein modeling and life sciences research. She shares how tools like AlphaFold and large language models are accelerating drug targeting, predicting allergen cross-reactivity, and translating learnings from human biology to agricultural innovation. This episode is sponsored by Deloitte. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

n this episode of Psychedelics Today, kicking of Psychedelic Science 2025 week in Denver, we sit down with Jonathan Dicksinson, Chief Executive Officer, and Trevor Millar, Chief Operations Officer of Ambio Life Sciences – one of the world's leading ibogaine clinics – to explore the potential of ibogaine for addiction, neuroregeneration, and how ethics, honoring experience, and sustainability will be key to delivering ibogaine at scale.  Trevor shares his early work supporting marginalized populations in Vancouver's Downtown Eastside, which led to the founding of Liberty Root, one of Canada's first ibogaine clinics. Jonathan reflects on his apprenticeship in Mexican clinics, years of international advocacy with the Global Ibogaine Therapy Alliance, and drafting the first set of clinical guidelines for ibogaine detoxification. Together with paramedic and ibogaine safety protocols expert Jose Inzunza, they co-founded Ambio in Tijuana in 2021. They discuss: The unique safety standards Ambio has pioneered – including industry-wide clinical protocols and magnesium therapy to mitigate cardiac risk. Their scale: over 3,000 patients treated, with 100+ clients per month across five dedicated houses in Baja California. Ambio's groundbreaking neuroregenerative program for Parkinson's, MS, and traumatic brain injury – which has already drawn patients like Brett Favre and Clay Walker. How ibogaine appears to drive profound physiological change – including evidence of TBI reversal as shown in Stanford's 2024 study on Special Forces veterans. Why ibogaine isn't just a molecule – it opens a long-lasting “critical period” of neuroplasticity that must be supported with preparation, integration, and holistic care. The deeper story of sourcing: through his company Terragnosis, Jonathan is the only person with a legal export license for Tabernanthe iboga from Gabon, and Ambio is setting a precedent for reciprocal and ethical global supply chains. Their cautionary perspective on Texas' $50M push toward ibogaine clinical trials – and why the traditional “one drug, one indication” model misses the complexity and promise of psychedelic healing. They also make a compelling case that Ambio is already modeling what the future of psychedelic care should look like – not a single drug in a sterile clinical setting, but a comprehensive, integrated protocol combining preparation, medical oversight, and deep integration. “Start with the end in mind,” Trevor urges – Ambio isn't just part of the movement; it's the blueprint for how ibogaine could be delivered worldwide. Links: Ambio Website: https://ambio.life/ Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis (Frontiers in Immunology, Feb 2025) Magnesium–ibogaine therapy in veterans with traumatic brain injuries (Nature Medicine, Jan 2024) Ibogaine reduced severe neuropathic pain associated with a case of brachial plexus nerve root avulsion (Frontiers in Pain Research, Aug 2023) Novel treatment of opioid use disorder using ibogaine and iboga in two adults (Journal of Psychedelic Studies, Jan 2020) Clinical Guidelines for Ibogaine-Assisted Detoxification Ambio Life Sciences Launches World's First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions Bios:  Jonathan Dickinson is the Chief Executive Officer and Co-Founder of Ambio Life Sciences. One of the world's leading experts on ibogaine, Jonathan brings over 15 years of experience in clinical care, traditional practice, and psychedelic research to his leadership at Ambio. A Mexico-licensed psychologist and former Executive Director of the Global Ibogaine Therapy Alliance, he authored the field's foundational safety guidelines and has published widely on ibogaine's therapeutic, cultural, and ecological significance. He holds the only active export license for Tabernanthe iboga root, led the first Nagoya-compliant export from Gabon, and was initiated into the Dissoumba/Fang tradition of Bwiti in 2014 and the Missoko tradition in 2022. He has co-authored peer-reviewed research on ibogaine's potential for trauma, TBI, pain, MS, and Parkinson's. At Ambio, he leads strategy, research, and innovation – advancing a globally scalable model of care that bridges tradition, science, and integrity. Trevor Millar is the Chief Operating Officer and Co-Founder of Ambio Life Sciences. A social entrepreneur and pioneer in ibogaine advocacy and treatment, Trevor brings over a decade of experience supporting individuals through addiction recovery, trauma healing, and post-treatment integration. His background includes co-founding the Canadian Psychedelic Association and serving as Chair of the Board for MAPS Canada. He has co-authored peer-reviewed research on ibogaine's applications for trauma, TBI, and opioid use disorder, and has been featured in award-winning documentaries including DOSED and In Waves and War. Grounded in personal experience and guided by a philosophical approach to healing, Trevor is helping shape a new model for ethical, integrative psychedelic care on a global scale. At Ambio, Trevor leads operations, strategic partnerships, and client experience – bridging clinical care with systems design, education, and public advocacy.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Tom Wells, Director of Life Sciences at 4C Associates, reveals why -- and how -- smart procurement practices can make or break emerging biotech companies during critical growth stages. Tom shares insights into procurement tools and strategies that can deliver breakthrough solutions, how poor procurement practices can damage investor confidence, and why thinking about procurement as the front end of demand flow, not the back end of supply chain, can help drug developers avoid costly mistakes. This episode of the Business of Biotech is brought to you by Ecolab. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Meet Dr. Bo Wen, a staff research scientist, AGI specialist, cloud architect, and tech lead in digital health at IBM. He's joining us to discuss his perspective on the rapid evolution of AI – and what it could mean for the future of human communication… With deep expertise in generative AI, human-AI interaction design, data orchestration, and computational analysis, Dr. Wen is pushing the boundaries of how we understand and apply large language models. His interdisciplinary background blends digital health, cognitive science, computational psychiatry, and physics, offering a rare and powerful lens on emerging AI systems. Since joining IBM in 2016, Dr. Wen has played a key role in the company's Healthcare and Life Sciences division, contributing to innovative projects involving wearables, IoT, and AI-driven health solutions. Prior to IBM, he earned his Ph.D. in Physics from the City University of New York and enjoyed a successful career as an experimental physicist. In this conversation, we explore: How Dr. Wen foresaw the AI breakthrough nearly a decade ago The implications of AGI for communication, reasoning, and human-AI collaboration How large language models work. What AI needs to understand to predict words in sentences.  Want to dive deeper into Dr. Wen's work? Learn more here! Episode also available on Apple Podcasts: http://apple.co/30PvU9C